Year: 2018
Type: Proceeding article
Title: Evaluation of the osteoporosis risk factors in postmenopausal women on Ibandronic acid treatment
Author: Mladenovska Stojkoska, Ivana
Author: Shubeska Stratrova, Slavica
Author: Jovanovska Mishevska, Sasha
Author: Markovikj Temelkova, Snezhana
Author: Bitoska, Iskra
Author: Adamova, Katerina
Author: Gerazova, Marija
Abstract: Introduction: The aim of this study was to evaluate the risk factors for osteoporosis in postmenopausal women with osteoporosis treated with ibandronic acid. Matherials and methods: Examinees were 22 postmenopausal women with Ibandronic acid ampular treatment for osteoporosis. Risk factors for osteoporosis were evaluated as well as ionized Ca (iCa), PTH, vitamin D (D), HBA1C, and spine and hip BMD and BMC (g/cm2). Resuts: All examinees had contraindications for oral bisphosphonate treatment. They had mean BMI values 25.57±4.8kg/m2, no one <19kg/m2. Mean age was 64.89±7.06 yr., all >45 years. Mean menopause on age of 45.13±5.89yr, 53.75% before the age of 45yr. and 21.43% had ovariectomy. Fracture had 31.03% of the examinees with mean age of 67.44±5.2yr. A greater reduction in body height than 3cm had 57.89% of patients, and 14.29% received corticotherapy. No one consumed alcohol, 34.48% smoked moderalety up to 1 box per day. Physical activity for less than 30 minutes was in 39.29% of subjects, 22.22% had sunbathing less than 10 min/day, HTA had 73% and DM type 2 50%, only two were on insulin with good glycoregulation. Average mean HBA1C was 6.33±1.29%. Osteoporosis was generally detected before 7.09±4.33 years. All of them received Sol Vigantol 3 gutts a day and calcium preparation. Mean D levels were 32.85±11.57 ng/ml, mean iCa levels were 1.2±0.29mmol/l, mean PTH levels were 58.64±21.98 pg/ml, L1-L4 was 84.55±7.51%. L1-L4 mean BMC 0.86±0.08 gr/cm2, L1-L4 T score -2.64±0.71 and left hip total -1.72±1.02, and in patients with fracture -2.17±1.07. Right hip total -2.18±0.96 in patients with fracture, mean value for the whole group -1.72 ± 0.93. Conclusion: Postmenopausal women treated with i.v.ibandronate had several risk factor, older age, early menopause, DM type 2, arterial hypertension, fracture, lower height, corticotreatment, reduced physical activity, no sunbathing, lower BMC and BMD.
Publisher:
Relation: Fifth Macedonian Congress of Endocrinology with international participation, 10 - 13 May, Ohrid
Identifier: oai:repository.ukim.mk:20.500.12188/16782
Identifier: http://hdl.handle.net/20.500.12188/16782
